{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:33:28Z","timestamp":1793262808464,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T00:00:00Z","timestamp":1440633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>The development of robust and well-characterized methods of production of cell therapies has become increasingly important as therapies advance through clinical trials toward approval. A successful cell therapy will be a consistent, safe, and effective cell product, regardless of the cell type or application. Process development strategies can be developed to gain efficiency while maintaining or improving safety and quality profiles. This review presents an introduction to the process development challenges of cell therapies and describes some of the tools available to address production issues. This article will provide a summary of what should be considered to efficiently advance a cellular therapy from the research stage through clinical trials and finally toward commercialization. The identification of the basic questions that affect process development is summarized in the target product profile, and considerations for process optimization are discussed. The goal is to identify potential manufacturing concerns early in the process so they may be addressed effectively and thus increase the probability that a therapy will be successful.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Significance<\/jats:title>\n                  <jats:p>The present study contributes to the field of cell therapy by providing a resource for those transitioning a potential therapy from the research stage to clinical and commercial applications. It provides the necessary steps that, when followed, can result in successful therapies from both a clinical and commercial perspective.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5966\/sctm.2014-0294","type":"journal-article","created":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T01:59:25Z","timestamp":1440727165000},"page":"1155-1163","source":"Crossref","is-referenced-by-count":145,"title":["Concise Review: Process Development Considerations for Cell Therapy"],"prefix":"10.1093","volume":"4","author":[{"given":"Andrew","family":"Campbell","sequence":"first","affiliation":[{"name":"International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada"},{"name":"Thermo Fisher Scientific, Inc., Grand Island, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brieva","sequence":"additional","affiliation":[{"name":"International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada"},{"name":"Celgene Cellular Therapeutics, Warren, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Raviv","sequence":"additional","affiliation":[{"name":"International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada"},{"name":"Pluristem Therapeutics Inc., Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Rowley","sequence":"additional","affiliation":[{"name":"International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada"},{"name":"Rooster Bio Inc., Frederick, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Niss","sequence":"additional","affiliation":[{"name":"International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada"},{"name":"Novartis Pharmaceuticals, Morris Plains, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey","family":"Brandwein","sequence":"additional","affiliation":[{"name":"International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada"},{"name":"Pall Life Sciences (division of Pall Corp), Port Washington, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Oh","sequence":"additional","affiliation":[{"name":"International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada"},{"name":"Stem Cell Group, Bioprocessing Technology Institute, A*STAR, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohad","family":"Karnieli","sequence":"additional","affiliation":[{"name":"International Society for Cellular Therapy Process and Product Development Subcommittee, Vancouver, British Columbia, Canada"},{"name":"Pluristem Therapeutics Inc., Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,8,27]]},"reference":[{"key":"2021122704421905100_R1","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-76643-0","volume-title":"Current Trends in Monoclonal Antibody Development and Manufacturing","author":"Shire","year":"2010"},{"issue":"suppl","key":"2021122704421905100_R2","first-page":"4","article-title":"Emerging challenges in cell therapy manufacturing: Solutions from monoclonal antibodies","volume":"10","author":"Jones","year":"2012","journal-title":"Bioprocess Int"},{"key":"2021122704421905100_R3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.5966\/sctm.2013-0050","article-title":"Concise review: Guidance in developing commercializable autologous\/patient-specific cell therapy manufacturing","volume":"2","author":"Eaker","year":"2013","journal-title":"Stem Cells Translational Medicine"},{"key":"2021122704421905100_R4"},{"key":"2021122704421905100_R5","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.tibtech.2009.06.006","article-title":"Roadmap for implementation of quality by design (QbD) for biotechnology products","volume":"27","author":"Rathore","year":"2009","journal-title":"Trends Biotechnol"},{"key":"2021122704421905100_R6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1208\/s12249-010-9566-x","article-title":"Quality by design and process analytical technology for sterile products--where are we now?","volume":"12","author":"Riley","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"2021122704421905100_R7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00216-010-3781-x","article-title":"Process analytical technology (PAT) for biopharmaceutical products","volume":"398","author":"Rathore","year":"2010","journal-title":"Anal Bioanal Chem"},{"key":"2021122704421905100_R8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1385\/ABAB:135:2:101","article-title":"Statistical experimental design for bioprocess modeling and optimization analysis: Repeated-measures method for dynamic biotechnology process","volume":"135","author":"Lee","year":"2006","journal-title":"Appl Biochem Biotechnol"},{"key":"2021122704421905100_R9","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/btpr.67","article-title":"Bioprocess optimization using design-of-experiments methodology","volume":"24","author":"Mandenius","year":"2008","journal-title":"Biotechnol Prog"},{"key":"2021122704421905100_R10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bej.2014.02.005","article-title":"A potentially scalable method for the harvesting of hMSCs from microcarriers","volume":"85","author":"Nienow","year":"2014","journal-title":"Biochem Eng J"},{"key":"2021122704421905100_R11","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/rme.10.60","article-title":"Shear stress induces osteogenic differentiation of human mesenchymal stem cells","volume":"5","author":"Yourek","year":"2010","journal-title":"Regen Med"},{"key":"2021122704421905100_R12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF02931883","article-title":"Development of high density mammalian cell culture system for the production of tissue-type plasminogen activator","volume":"5","author":"Park","year":"2000","journal-title":"Biotechnol Bioprocess Eng"},{"key":"2021122704421905100_R13","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/btpr.1704","article-title":"Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor\u2122. Part I. Effect of the cell density on the process","volume":"29","author":"Clincke","year":"2013","journal-title":"Biotechnol Prog"},{"key":"2021122704421905100_R14","first-page":"177","article-title":"Approaches to optimizing animal cell culture process: Substrate metabolism regulation and protein expression improvement","volume":"113","author":"Zhang","year":"2009","journal-title":"Adv Biochem Eng Biotechnol"},{"key":"2021122704421905100_R15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/rme.11.112","article-title":"Peak serum: Implications of serum supply for cell therapy manufacturing","volume":"7","author":"Brindley","year":"2012","journal-title":"Regen Med"},{"key":"2021122704421905100_R16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/ten.tec.2010.0320","article-title":"Agitation can induce differentiation of human pluripotent stem cells in microcarrier cultures","volume":"17","author":"Leung","year":"2011","journal-title":"Tissue Eng Part C Methods"},{"key":"2021122704421905100_R17","first-page":"34","article-title":"Evaluation of single-use fluidized bed centrifuge system for mammalian cell harvesting","volume":"25","author":"Ko","year":"2012","journal-title":"Biopharm Int"},{"issue":"suppl","key":"2021122704421905100_R18","first-page":"38","article-title":"Downstream technology landscape for large-scale therapeutic cell processing","volume":"11","author":"Pattasseril","year":"2013","journal-title":"Bioprocess Int"},{"key":"2021122704421905100_R19","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/ten.tec.2012.0146","article-title":"Microcarrier suspension cultures for high-density expansion and differentiation of human pluripotent stem cells to neural progenitor cells","volume":"19","author":"Bardy","year":"2013","journal-title":"Tissue Eng Part C Methods"},{"key":"2021122704421905100_R20"},{"key":"2021122704421905100_R21"},{"key":"2021122704421905100_R22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2217\/rme.11.28","article-title":"Cell therapy industry: Billion dollar global business with unlimited potential","volume":"6","author":"Mason","year":"2011","journal-title":"Regen Med"},{"issue":"suppl","key":"2021122704421905100_R23","first-page":"16","article-title":"Meeting lot-size challenges of manufacturing adherent cells for therapy","volume":"10","author":"Rowley","year":"2012","journal-title":"Bioprocess Int"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.5966%2Fsctm.2014-0294","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.5966%2Fsctm.2014-0294","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/4\/10\/1155\/41864868\/stcltm_4_10_1155.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/4\/10\/1155\/41864868\/stcltm_4_10_1155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:49:21Z","timestamp":1642560561000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/4\/10\/1155-1163\/6387843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,27]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,8,27]]},"published-print":{"date-parts":[[2015,10,1]]}},"URL":"https:\/\/doi.org\/10.5966\/sctm.2014-0294","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,10,1]]},"published":{"date-parts":[[2015,8,27]]}}}